CXCR4 chemokine receptor antagonists: perspectives in SCLC

Bibliography

• Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol2006;24(28):4539-44
   PubMed Web of Science ®Google Scholar
• Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J of Surg pathol2002;26(9):1184-97
   PubMed Web of Science ®Google Scholar
• Bezwoda WR, Lewis D, Livini N. Bone marrow involvement in anaplastic small cell lung cancer. Diagnosis, hematologic features, and prognostic implications. Cancer1986;58(8):1762-5
   PubMed Web of Science ®Google Scholar
• Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell2002;1(1):49-52
   PubMed Web of Science ®Google Scholar
• Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest2007;132(3 Suppl):324S-39S
   PubMed Web of Science ®Google Scholar
• Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer2008;113(1):5-21
   PubMed Web of Science ®Google Scholar
• Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med1999;5(6):662-8
   PubMed Web of Science ®Google Scholar
• Hartmann TN, Burger M, Burger JA. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer. J Biol Regul Homeost Agents2004;18(2):126-30
   PubMed Web of Science ®Google Scholar
• Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. International journal of radiation biology2007;83(11-12):733-41
   PubMed Web of Science ®Google Scholar
• Zhong L, Roybal J, Chaerkady R, et al. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res2008;68(17):7237-45
   PubMed Web of Science ®Google Scholar
• Ho CC, Liao WY, Wang CY, et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med2008;177(7):763-70
   PubMed Web of Science ®Google Scholar
• Nazareth MR, Broderick L, Simpson-Abelson MR, et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol2007;178(9):5552-62
   PubMed Web of Science ®Google Scholar
• Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell2005;7(6):513-20
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature2007;449(7162):557-63
   PubMed Web of Science ®Google Scholar
• Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle2006;5(15):1597-601
   PubMed Web of Science ®Google Scholar
• Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood1999;93(5):1658-67
   PubMed Web of Science ®Google Scholar
• Moore KA, Lemischka IR. Stem cells and their niches. Science2006;311(5769):1880-5
   PubMed Web of Science ®Google Scholar
• Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell2008;132(4):598-11
   PubMed Web of Science ®Google Scholar
• Laird DJ, von Andrian UH, Wagers AJ. Stem cell trafficking in tissue development, growth, and disease. Cell2008;132(4):612-30
   PubMed Web of Science ®Google Scholar
• Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol2006;6(2):107-16
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med1997;3(7):730-7
   PubMed Web of Science ®Google Scholar
• Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature2003;423(6937):255-60
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature1994;367(6464):645-8
   PubMed Web of Science ®Google Scholar
• Hope KJ, Jin L, Dick JE. Human acute myeloid leukemia stem cells. Arch Med Res2003;34(6):507-14
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity2006;25(6):977-88
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell2007;11(1):69-82
   PubMed Web of Science ®Google Scholar
• Yang ZJ, Wechsler-Reya RJ. Hit ‘em where they live: targeting the cancer stem cell niche. Cancer Cell2007;11(1):3-5
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell death differ2008;15(3):504-14
   PubMed Web of Science ®Google Scholar
• Donnenberg VS, Luketich JD, Landreneau RJ, et al. Tumorigenic epithelial stem cells and their normal counterparts. Ernst Schering Found Symp Proc2006;(5):245-63
   PubMedGoogle Scholar
• Levina V, Marrangoni AM, DeMarco R, et al. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE2008;3(8):e3077
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity2000;12(2):121-7
   PubMed Web of Science ®Google Scholar
• Loetscher P, Moser B, Baggiolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol2000;74:127-80
   PubMedGoogle Scholar
• Baggiolini M. Chemokines and leukocyte traffic. Nature1998;392(6676):565-8
   PubMed Web of Science ®Google Scholar
• Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol2001;2(2):123-8
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA1994;91(6):2305-9
   PubMed Web of Science ®Google Scholar
• Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature1996;382(6594):829-33
   PubMed Web of Science ®Google Scholar
• Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature1996;382(6594):833-5. Published erratum appears in Nature 1996;384(6606):288
   PubMed Web of Science ®Google Scholar
• Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science1996;272(5263):872-7
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature1996;382(6592):635-8
   PubMed Web of Science ®Google Scholar
• Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract [see comments]. Nature1998;393(6685):591-4
   PubMed Web of Science ®Google Scholar
• Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development [see comments]. Nature1998;393(6685):595-9
   PubMed Web of Science ®Google Scholar
• Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA1998;95(16):9448-53
   PubMed Web of Science ®Google Scholar
• Boldajipour B, Mahabaleshwar H, Kardash E, et al. Control of chemokine-guided cell migration by ligand sequestration. Cell2008;132(3):463-73
   PubMed Web of Science ®Google Scholar
• Sierro F, Biben C, Martinez-Munoz L, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci USA2007;104(37):14759-64
   PubMed Web of Science ®Google Scholar
• Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet2003;34(1):70-4
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature2001;410(6824):50-6
   PubMed Web of Science ®Google Scholar
• Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science1999;283(5403):845-8
   PubMed Web of Science ®Google Scholar
• Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature2005;435(7044):969-73
   PubMed Web of Science ®Google Scholar
• Wright DE, Bowman EP, Wagers AJ, et al. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med2002;195(9):1145-54
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med2005;201(8):1307-18
   PubMed Web of Science ®Google Scholar
• Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future oncol (London, England)2007;3(1):19-27
   PubMedGoogle Scholar
• Abraham M, Biyder K, Begin M, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells2007;25(9):2158-66
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell2005;121(3):335-48
   PubMed Web of Science ®Google Scholar
• Kijima T, Maulik G, Ma PC, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res2002;62(21):6304-11
   PubMed Web of Science ®Google Scholar
• Burger M, Glodek A, Hartmann T, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene2003;22(50):8093-101
   PubMed Web of Science ®Google Scholar
• Hartmann TN, Burger JA, Glodek A, et al. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene2005;24(27):4462-71
   PubMed Web of Science ®Google Scholar
• Tang CH, Tan TW, Fu WM, Yang RS. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis2008;29(1):35-43
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Lutz M, et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir crit Care Med2003;167(12):1676-86
   PubMed Web of Science ®Google Scholar
• Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res2002;62(6):1832-7
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Y, Song W, et al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal2005;17(12):1578-92
   PubMed Web of Science ®Google Scholar
• Hart CA, Brown M, Bagley S, et al. Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer2005;92(3):503-12
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood2006;107(5):1761-7
   PubMed Web of Science ®Google Scholar
• Burger JA, Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol2007;137(4):288-96
   PubMed Web of Science ®Google Scholar
• Liotta LA. An attractive force in metastasis. Nature2001;410(6824):24-5
   PubMed Web of Science ®Google Scholar
• Li ZW, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev2006;20(6):333-42
   PubMed Web of Science ®Google Scholar
• Nakashima H, Masuda M, Murakami T, et al. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob Agents Chem1992;36(6):1249-55
   PubMed Web of Science ®Google Scholar
• Masuda M, Nakashima H, Ueda T, et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). Biochem Biophys Res Commun1992;189(2):845-50
   PubMed Web of Science ®Google Scholar
• De Clercq E, Yamamoto N, Pauwels R, et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA1992;89(12):5286-90
   PubMed Web of Science ®Google Scholar
• De Clercq E, Yamamoto N, Pauwels R, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother1994;38(4):668-74
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Filion LG, Diaz-Mitoma F, et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses2001;17(6):475-86
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Grovit-Ferbas K, Sharron MP, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med1997;186(8):1395-400
   PubMed Web of Science ®Google Scholar
• Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med1997;186(8):1383-8
   PubMed Web of Science ®Google Scholar
• Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med1997;186(8):1389-93
   PubMed Web of Science ®Google Scholar
• De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov2003;2(7):581-7
   PubMed Web of Science ®Google Scholar
• Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett2002;527(1-3):255-62
   PubMed Web of Science ®Google Scholar
• Fricker SP, Anastassov V, Cox J, et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol2006;72(5):588-96
   PubMed Web of Science ®Google Scholar
• Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med1998;4(1):72-7
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother2000;44(6):1667-73
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr2004;37(2):1253-62
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood2003;102(8):2728-30
   PubMed Web of Science ®Google Scholar
• Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22(6):1095-102
   PubMed Web of Science ®Google Scholar
• Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood2008;112(4):990-8
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. FDA Approval for Plerixafor. http://wwwcancergov/cancertopics/druginfo/fda-plerixafor2008
   Google Scholar
• Micallef I, Stiff PJ, DiPersio JF, et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor)+G-CSF for patients who failed primary mobilization: results from the phase III (3101-NHL) study. Blood2007;110(11):185a
   Google Scholar
• DiPersio JF, Micallef INM, Stiff PJ, et al. 12 months report from the phase 3 study of Plerixafor+G-CSF VS. Placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood2008;112(11):414
   Google Scholar
• Uy GL, Rettig MP, Ramirez P, et al. Kinetics of human and murine mobilization of acute myelogenous leukemia in response to AMD3100. Blood2007;110(11):265a
   Google Scholar
• Fierro FA, Brenner S, Oelschlaegel U, et al. Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia. Leukemia published online 2008 Jul 10
   Google Scholar
• Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res2004;64(23):8604-12
   PubMed Web of Science ®Google Scholar
• Huang YC, Hsiao YC, Chen YJ, et al. Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. Biochem Pharmacol2007;74(12):1702-12
   PubMed Web of Science ®Google Scholar
• Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res2004;64(22):8420-7
   PubMed Web of Science ®Google Scholar
• Ohira S, Sasaki M, Harada K, et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol2006;168(4):1155-68
   PubMed Web of Science ®Google Scholar
• Ottaiano A, Franco R, Aiello Talamanca A, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res2006;12(9):2795-803
   PubMed Web of Science ®Google Scholar
• Scala S, Giuliano P, Ascierto PA, et al. Human melanoma metastases express functional CXCR4. Clin Cancer Res2006;12(8):2427-33
   PubMed Web of Science ®Google Scholar
• Hong X, Jiang F, Kalkanis SN, et al. SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Lett2006;236(1):39-45
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res2002;62(20):5930-8
   PubMed Web of Science ®Google Scholar
• Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA2003;100(23):13513-8
   PubMed Web of Science ®Google Scholar
• Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood2005;106(5):1824-30
   PubMed Web of Science ®Google Scholar
• Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res2004;64(8):2817-24
   PubMed Web of Science ®Google Scholar
• Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood2007;109(7):2708-17
   PubMed Web of Science ®Google Scholar
• Stone ND, Dunaway SB, Flexner C, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother2007;51(7):2351-8
   PubMed Web of Science ®Google Scholar
• Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA2003;100(7):4185-90
   PubMed Web of Science ®Google Scholar
• Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun1998;253(3):877-82
   PubMed Web of Science ®Google Scholar
• Tamamura H, Omagari A, Hiramatsu K, et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett2001;11(14):1897-902
   PubMed Web of Science ®Google Scholar
• Trent JO, Wang ZX, Murray JL, et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem2003;278(47):47136-44
   PubMed Web of Science ®Google Scholar
• Zhang WB, Navenot JM, Haribabu B, et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem2002;277(27):24515-21
   PubMed Web of Science ®Google Scholar
• Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett2003;550(1-3):79-83
   PubMed Web of Science ®Google Scholar
• Takenaga M, Tamamura H, Hiramatsu K, et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun2004;320(1):226-32
   PubMed Web of Science ®Google Scholar
• Tamamura H, Fujisawa M, Hiramatsu K, et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett2004;569(1-3):99-104
   PubMed Web of Science ®Google Scholar
• Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia2003;17(7):1294-300
   PubMed Web of Science ®Google Scholar
• Juarez J, Dela Pena A, Baraz R, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia2007;21(6):1249-57
   PubMed Web of Science ®Google Scholar
• Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res2005;65(5):1700-9
   PubMed Web of Science ®Google Scholar
• Mori T, Doi R, Koizumi M, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther2004;3(1):29-37
   PubMed Web of Science ®Google Scholar
• Kohara H, Omatsu Y, Sugiyama T, et al. Development of plasmacytoid dendritic cells in bone marrow stromal cell niches requires CXCL12-CXCR4 chemokine signaling. Blood2007;110(13):4153-60
   PubMed Web of Science ®Google Scholar
• Kabashima K, Shiraishi N, Sugita K, et al. CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol2007;171(4):1249-57
   PubMed Web of Science ®Google Scholar
• Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol2004;5(9):943-52
   PubMed Web of Science ®Google Scholar
• Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol2002;3(7):687-94
   PubMed Web of Science ®Google Scholar
• Endres MJ, Clapham PR, Marsh M, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell1996;87(4):745-56
   PubMed Web of Science ®Google Scholar
• D'Apuzzo M, Rolink A, Loetscher M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol1997;27(7):1788-93
   PubMed Web of Science ®Google Scholar
• Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood1999;94(11):3658-67
   PubMed Web of Science ®Google Scholar
• Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res2002;62(11):3106-12
   PubMed Web of Science ®Google Scholar
• Chen GS, Yu HS, Lan CC, et al. CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Bri J Derm2006;154(5):910-8
   PubMed Web of Science ®Google Scholar
• Engl T, Relja B, Marian D, et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia2006;8(4):290-301
   PubMed Web of Science ®Google Scholar
• Baribaud F, Edwards TG, Sharron M, et al. Antigenically distinct conformations of CXCR4. J Virol2001;75(19):8957-67
   PubMed Web of Science ®Google Scholar
• Farzan M, Babcock GJ, Vasilieva N, et al. The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1 entry. J Biol Chem2002;277(33):29484-9
   PubMed Web of Science ®Google Scholar
• Wong D, Korz W. Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clin Cancer Res2008;14(24):7975-80
   PubMed Web of Science ®Google Scholar
• Perez LE, Alpdogan O, Shieh JH, et al. Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Exp Hematol2004;32(3):300-7
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis2008;25(3):201-11
   PubMed Web of Science ®Google Scholar
• Hachet-Haas M, Balabanian K, Rohmer F, et al. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J Biol Chem2008;283(34):23189-99
   PubMed Web of Science ®Google Scholar
• Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet2007;8(3):173-84
   PubMed Web of Science ®Google Scholar
• Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res2003;63(16):4801-4
   PubMed Web of Science ®Google Scholar
• Liang Z, Wu H, Reddy S, et al. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun2007;363(3):542-6
   PubMed Web of Science ®Google Scholar